Product Name:
CDC7-pT376
Product Number:
ab-pk558
Target Full Name: Cell division cycle 7-related protein kinase
Target Alias: CDC7- related kinase; CDC7L1; Cell division cycle 7; HsCdc7; Hsk1; HuCdc7; Kinase CDC7; MuCdc7
Product Type Specific: CDC7 protein kinase phosphosite-specific antibody
Antibody Code: PK558
Antibody Target Type: Phosphosite-specific
Antibody Phosphosite: T376
Protein UniProt: O00311
Protein SigNET: CDC7
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Human CDC7 sequence peptide Cat. No.: PE-04AJE99
Antibody Immunogen Sequence: RAG(pT)PGF(bA)C
Antibody Immunogen Description: Corresponds to amino acid residues R373 to F379; in the protein kinase catalytic domain activation T loop region between subdomains VII and VIII. T376 phosphorylation was originally suggested to be stimulatory based on loss of phosphotransferase activity with an alanine substitution. However, it is predicted to be inhibitory for phosphotransferase activity. This is one of the major in vivo phosphorylation sites in CDC7 (≥13 reports from high throughput mass spectrometry studies recorded in PhosphoSitePlus). CDC7 is known to be phosphorylated at this site in vitro by CDK1 (CDC2), and CDK2.
Production Method: The immunizing peptide was produced by solid phase synthesis on a multipep peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from these animals was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris.This antibody was also subject to negative purification over phosphotyrosine-agarose.
Antibody Modification: Unconjugated. Contact KInexus if you are interest in having the antibody biotinylated or coupled with fluorescent dyes.
Antibody Concentration: 1 mg/ml
Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 2 µg/ml for immunoblotting
Antibody Potency: Very weak immunoreactivity of a target-sized protein by Western blotting in sea star oocytes. Very strong immunoreactivity with immunogen peptide on dot blots.
Antibody Species Reactivity: This antibody detects the target phosphoprotein in the following species due to conservation of amino acid sequence: Human | Rhesus Macaque | Mouse | Chicken | Frog.
Antibody Positive Control: The observed molecular mass of the processed target protein on SDS-PAGE gels is reported to be around 62-67 kDa.
Antibody Specificity: High-very high
Antibody Cross Reactivity: No significant cross-reactive proteins detected in in A431, HeLa and Jurkat cells.
Related Product 1: CDC7 (373-379) pT376 antibody blocking peptide (Cat. No.: PE-04AJE99)
Related Product 2: CDK1-3 Selectide kinase substrate peptide (Cat. No.: PE-01BGO99)
Scientific Background: CDC7 (Cell Division Cycle 7) is a 64 kDa protein-serine/threonine kinase that is important for the G1/S transition in the cell division cycle. The protein product may phosphorylate critical substrates in G1/S phase transition and DNA replication. It regulates the initiation of DNA replication by phosphorylating the MCM2-7 helicase complex at the G1/S transition. CDC7 phosphorylates MCM2 and MCM3. It is activated by phosphorylation at Thr-376 in the kinase activation loop by CDK1 and CDK2. It also requires binding to activator of S-phase kinase (ASK)/DBF4B to be fully stimulated. It is primarily found in the nucleus (nucleoplasm), and it also localizes to the cytokinetic bridge and mitotic spindle. It is primarily found in the nucleus (nucleoplasm), and it also localizes to the cytokinetic bridge and mitotic spindle. It may be an oncoprotein (OP) as over-expression of CDC7 may be associated with neoplastic tumour transformation. RNAi inhibition of CDC7 induces an abortive S phase and apoptotic cell death in p53-mutant ErbB2-overexpressing and triple-negative (ER-/PR-/ErbB2-) breast cancer cell lines, but not in untransformed breast epithelial cells. Consequently, CDC7 appears to represent a potent and highly specific anticancer target in ErbB2-overexpressing and triple-negative breast cancers. It is also a suitable target for treatment of other types of cancer, including pancreatic and livercancer. This description may include information annotated by UniProt and/or Google AI.